Showing results (31-40 of 154) with videos related to

Sort By:
Pageof 16
Scientific Reports|April 29, 2024
Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancerShogo Nakamoto, Tadahiko Shien, Takayuki Iwamoto, et al.
Pathology International|May 31, 2024
The specific shapes of capillaries are associated with worse prognosis in patients with invasive breast cancerHnin-Wint-Wint Swe, Masayoshi Fujisawa, Toshiaki Ohara, et al.
Acta Medica Okayama|March 2, 2006
Gefitinib, an epidermal growth factor receptor blockade agent, shows additional or synergistic effects on the radiosensitivity of esophageal cancer cells in vitroNaruto Taira, Hiroyoshi Doihara, Tetsuya Oota, et al.
Chinese Clinical Oncology|September 11, 2024
Primary angiosarcoma of the breast: a literature reviewYidan Zhu, Shogo Nakamoto, Takahiro Tsukioki, et al.
Breast Cancer (Tokyo, Japan)|August 22, 2022
Predictive value of immune genomic signatures from breast cancer cohorts containing data for both response to neoadjuvant chemotherapy and prognosis after surgeryYidan Zhu, Takayuki Iwamoto, Yukiko Kajiwara, et al.
Surgery Today|March 5, 2004
Less invasive surgery for primary hyperparathyroidism based on preoperative 99mTc-hexakis-2-methoxyisobutylisonitrile imaging findingsNaruto Taira, Hiroyoshi Doihara, Fumikata Hara, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 16, 2024
Real-World Comparative Analysis of Trastuzumab Originator and Biosimilars: Safety, Efficacy, and Cost EffectivenessTomoka Mamori, Maki Tanioka, Kenji Takada, et al.
Breast Cancer (Tokyo, Japan)|December 18, 2004
PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839)Tadahiko Shien, Hiroyoshi Doihara, Humikata Hara, et al.
Japanese Journal of Clinical Oncology|July 3, 2021
A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncology Group Study (JCOG1607, HERB TEA study)Akihiko Shimomura, Kenji Tamura, Kiyo Tanaka, et al.
Breast Cancer (Tokyo, Japan)|March 13, 2012
Expression of ALDH1 in axillary lymph node metastases is a prognostic factor of poor clinical outcome in breast cancer patients with 1-3 lymph node metastasesTomohiro Nogami, Tadahiko Shien, Takehiro Tanaka, et al.
Pageof 16